<DOC>
	<DOCNO>NCT01895829</DOCNO>
	<brief_summary>The goal clinical research study learn ferumoxytol , give time magnetic resonance imaging ( MRI ) , help researcher learn spread certain kind cancer . Ferumoxytol design deliver iron treat iron-deficiency anemia ( low red blood cell count ) patient chronic kidney disease . In study , use MRI contrast . Contrasts use doctor order see MRI image clearly .</brief_summary>
	<brief_title>Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI</brief_title>
	<detailed_description>Study Scans : If find eligible take part study , 2 study MRIs . These scan perform Center Advanced Biomedical Imaging ( CABI ) , South Campus Research Building MD Anderson . On Day 1 , 2 standard MRIs , part standard care . About hour 2 scan , receive ferumoxytol vein . Right , first study MRI . The study MRI perform way standard MRI perform . On Day 2 , 24 72 hour receive ferumoxytol , second study MRI . Additional Tests : On Days 1 3 , well 4 week first study MRI : - You physical exam . - Blood ( 2 teaspoon ) draw routine test and/or check iron level . On Day 2 : - You physical exam . - If one last month , PET-CT scan check status disease . Length Study : You study 4 week . You take study intolerable side effect unable scan reason . This investigational study . Ferumoxytol commercially available FDA-approved treatment iron deficiency anemia . Up 20 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<criteria>1 . Patients 18 year age old histologically cytologically confirm head neck squamous cell carcinoma melanoma 2 . Measurable clinical and/or radiographic polynodal disease define stage N2b , N2c N3 disease multiple involve lymph node define American Joint Committee Cancer ( AJCC ) cancer stag criterion 3 . Patients receive dispositioned receive Positron emission tomography ( PET ) computerize tomography ( CT ) [ PETCT ] scan within two week start definitive therapy head neck malignancy participation study . This imply patient must receive PETCT eligible study . 1 . Patients undergone definitive resection primary nodal disease well chemotherapy radiation therapy head neck primary tumor . 2 . Patients unable unwilling give write , informed consent undergo MRI imaging . 3 . Women childbearing potential ( A woman childbearing potential sexually mature woman undergone hysterectomy naturally postmenopausal least 24 consecutive month [ i.e. , menses time precede 24 consecutive month ] ) . Male partner must practice effective contraception ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) throughout study . 4 . Patients unable tolerate DCEMRI estimate GFR &lt; 60 ml/min/1.73m^2 . 5 . Contraindications iron supplementation include hemochromatosis , colitis , history GI bleeds , alcoholism , liver disease . Ferumoxytol contraindicate patient evidence iron overload and/or know hypersensitivity Feraheme component . Consequently , plan exclude patient symptom sign might cause iron overload . These include patient ( unexplained ) : arthritis ( include premature osteoarthritis ) , congestive heart failure cardiomyopathy , adultonset diabetes , secondary hypogonadism , increase skin pigmentation , patient persistently elevate serum ferritin explain underlying inflammatory/systemic disease , unless patient demonstrate fast transferrin saturation &lt; /= 0.45 . 6 . Patients evidence iron overload preimaging laboratory study . 7 . Patients contraindication gadoliniumbased contrast agent . 8 . Patients claustrophobia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Squamous cell carcinoma head neck</keyword>
	<keyword>HNSCC</keyword>
	<keyword>Magnetic resonance imaging</keyword>
	<keyword>MRI</keyword>
	<keyword>Ferumoxytol</keyword>
	<keyword>Ultra-small superparamagnetic iron oxide nanoparticle</keyword>
	<keyword>USPIO</keyword>
	<keyword>Contrast agent</keyword>
	<keyword>Dynamic contrast imaging</keyword>
	<keyword>DCI</keyword>
</DOC>